Press Release **For Immediate Dissemination**

Glenmark's consolidated revenue increases by 44 % to Rs. 7091 Mn for Q4-FY'10. Consolidated Net Profit was at 1026 million

- Specialty business registered sales growth of 62 %
  - India formulations business grew by 35 %
- Generics business registered sales growth of 23 %
  - US Generics business grew by 18 %

Mumbai, May 28, 2010: Glenmark Pharmaceuticals Limited (GPL), the research-led global integrated pharmaceutical company announced its fourth quarter results for the period ending March 31, 2010. Glenmark's consolidated revenue for the quarter was Rs. 7091.47 Mn [USD 152.81 Mn] as against Rs. 4910.84 Mn [USD 95.60 Mn], an increase of 44 %. Revenue from the generics business was at Rs. 2,732.86 Mn (USD 59.11 Mn), as against Rs. 2,218.81 Mn (USD 42.94 Mn), a growth of 23%. The Speciality formulation business revenue was at Rs. 4,358.61 Mn (USD 93.70 Mn) as against Rs. 2,692.03 Mn (USD 52.66 Mn) registering growth of 62%.

The Consolidated Net Profit for the fourth quarter was Rs.1,026.18 million as compared to a loss of Rs. 1,206.96 million for the previous corresponding quarter.

Commenting on the results Mr. Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals Limited mentions "The robust growth registered by the business in the fourth quarter augurs well for this financial year too. All businesses and regions have performed well and we continue to remain optimistic about growth for the current financial year."

For the financial year 2009-10, Glenmark's consolidated revenue increased to Rs. 24,848.46 Mn [USD 520.44 Mn] as against Rs. 20,930.17 Mn [USD 450.40 Mn], a growth of 19%. Revenue from the generics business was at Rs. 10,500.12 Mn (USD 219.92 Mn), as against Rs. 9,857.43 Mn (USD 212.12 Mn), registering growth of 7%. The Speciality formulation business registered revenue of Rs. 14,348.34 Mn (USD 300.52 Mn) as against Rs. 11,072.74 Mn (USD 238.28 Mn), registering growth of 30%. **The Consolidated Net Profit for the financial year was at Rs.3310.32 million as compared to Rs. 1934.73 million for the previous financial year, an increase of 71 %**

Specialty Business Q4 – FY 10

Sales for the formulation business in India increased to Rs. 2,184.03 Mn [USD 47.03 Mn] from Rs. 1,616.85 Mn [USD 31.95 Mn] in the previous corresponding quarter, recording a growth of 35%. Revenue from Africa, Asia and CIS region was at Rs. 1,369.71 Mn [USD 29.29 Mn] as against Rs. 422.87 Mn [USD 7.88 Mn] for the previous corresponding quarter, recording an increase of 224%.

Glenmark's revenue from its Latin American and Caribbean operations was at Rs. 345.86 Mn [USD 7.49 Mn] as against Rs. 268.76 Mn [USD 4.96 Mn] a growth of 29%. Glenmark Europe's operations recorded revenue of Rs. 459.01 Mn [USD 9.83 Mn] as compared to Rs. 383.55 Mn [USD 7.87 Mn] for the previous corresponding quarter, an increase of 20%.

Generics Business:

Glenmark Generics Inc., U.S.A. registered revenue of Rs. 1,852.30 Mn (USD 40.09 Mn) for the fourth quarter of FY'10 as against revenue of Rs. 1,563.60 Mn (USD 30.01 Mn), an increase of 18%. Revenue from sale of API to regulated and semi-regulated markets globally was Rs. 702.55 Mn [USD 15.18 Mn] for Q4 FY10 against Rs. 505.12 Mn [USD 9.95 Mn] for Q4 of the previous year, recording an increase of 39%.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.], Metabolic Disorders [diabetes, obesity, etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.

Disclaimer

"Glenmark Generics Limited ("Company"), a subsidiary of Glenmark Pharmaceuticals Limited is proposing, subject to market conditions and other considerations, a public issue of its equity shares and has filed a Draft Red Herring Prospectus with SEBI. The Draft Red Herring Prospectus is available on the website of SEBI at www.sebi.gov.in and the respective websites of the BRLMs at www.enam.com and www.kmcc.co.in.

Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" of the aforementioned Draft Red Herring Prospectus."

Disclaimer

This document has been prepared by Glenmark Pharmaceuticals Ltd. The information, statements and analysis made in this document describing company's objectives, projections and estimates are forward looking statements and progressive within the meaning of applicable Security Laws and Regulations. The analysis contained herein is based on numerous assumptions. Actual results may vary from those expressed or implied depending upon economic conditions, government policies and other incidental factors. No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment.

# # # #

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India
Tel: [+91 22] 40189919
Email : media@glenmarkpharma.com